z-logo
Premium
O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520
Author(s) -
Ufer Mike,
Rouzade-Dominguez Marie-Laure,
Huledal Gunilla,
Pezous Nicole,
Avrameas Alexandre,
David Olivier,
Kretz Sandrine,
Kucher Klaus,
Neumann Ulf,
Cha Jang-Ho,
Graf Ana,
Lopez-Lopez Cristina
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.351
Subject(s) - tolerability , medicine , placebo , pharmacodynamics , pharmacokinetics , dosing , adverse effect , asymptomatic , pharmacology , vital signs , anesthesia , gastroenterology , pathology , alternative medicine
Luc Tritsmans, Luc Van Nueten, Niels Andreassen, Sebastiaan Engelborghs, Janssen Research & Development, Beerse, Belgium; 2 Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M€ olndal, Sweden; Ortho-McNeil Pharmaceutical, Raritan, NJ, USA; Janssen Research & Development, Titusville, NJ, USA; 5 Hospital Mutua de Terrasa, Servicio de Neurologia, Terrassa, Spain; Hospital Universitario La Paz, Madrid, Spain; Hospital Clinico San Carlos, Servicio de Neurologia, Madrid, Spain; Fundaci o ACE, Barcelona, Alzheimer Treatment & Research Center, Barcelona, Spain; 9 Hospital Universitari La Fe Avinguda Abril Martorell, Valencia, Spain; Karolinska Institutet, Stockholm, Sweden; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium. Contact e-mail: jstreffe@its.jnj.com

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom